A post-authorization study to assess the safety and efficacy of Fanhdi (Double-inactivated human anti-hemophilic factor) in subjects with Von Willebrand disease (PostAuthorization Study with Fanhdi in VWD patient)

02/11/2018
22/02/2024
EU PAS number:
EUPAS25809
Study
Finalised
Subscribe
Download as PDF
Documents
Study protocol
Initial protocol

IG1403 Protocol V3.0 2018.05.18

English (872.73 KB - PDF) View document
Updated protocol

Protocolo v 4.0 (2021_01_20)_redacted

First published: 22/02/2024
English (7.88 MB - PDF) View document
Study results
Study results

2-synopsis_redacted

English (1.2 MB - PDF) View document
Study report
Other information